HALOZYME THERAPEUTICS INC (HALO)
US40637H1095 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 118.37M | 234.20M | 118.70M | 147.70M | 120.20M | |||
| Marketable Securities | 217.63M | 128.60M | 622.20M | 220.30M | 301.10M | |||
| Receivables | 234.21M | 231.10M | 91.00M | 97.70M | 59.40M | |||
| Inventories | 127.60M | 100.10M | 53.90M | 60.70M | 29.40M | |||
| Other Current Assets | 48.61M | 45.00M | 40.50M | 28.30M | 33.40M | |||
| Total Current Assets | 746.42M | 739.00M | 926.30M | 554.80M | 543.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 74.94M | 75.60M | 8.80M | 10.60M | 10.90M | |||
| Goodwill | 416.82M | 409.00M | N/A | N/A | N/A | |||
| Intangibles | 472.88M | 546.70M | N/A | N/A | N/A | |||
| Other Non-Current Assets | 22.20M | 71.20M | 169.30M | 14.60M | 11.60M | |||
| Total Non-Current Assets | 986.85M | 1.10B | 178.10M | 25.10M | 22.50M | |||
| TOTAL ASSETS | 1.73B | 1.84B | 1.10B | 579.90M | 565.90M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 13.30M | 89.40M | 397.20M | 19.50M | |||
| Accrued Expenses | 99.72M | 96.50M | 24.40M | 20.50M | 55.60M | |||
| Accounts Payable | 11.82M | 17.70M | 1.50M | 1.90M | 6.40M | |||
| Other Current Liabilities | 963.00K | 3.20M | 1.70M | 1.70M | 4.00M | |||
| Total Current Liabilities | 112.49M | 130.80M | 117.10M | 421.40M | 85.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.50B | 1.49B | 787.30M | 0.00 | 383.00M | |||
| Other Non-Current Liabilities | 37.72M | 48.20M | 3.10M | 7.50M | 5.40M | |||
| Total Non-Current Liabilities | 1.54B | 1.54B | 790.40M | 7.50M | 388.50M | |||
| TOTAL LIABILITIES | 1.65B | 1.67B | 907.50M | 428.90M | 474.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 90.55M | 143.20M | -58.90M | -474.60M | -603.70M | |||
| Additional Paid In Capital | 2.41M | 27.40M | 256.30M | 625.50M | 695.10M | |||
| Common Shares | 127.00K | 100.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -9.28M | -900.00K | -600.00K | 0.00 | 200.00K | |||
| Shares Outstanding | 126.77M | 135.20M | 137.50M | 135.00M | 136.70M | |||
| Tangible Book Value per Share | -6.36 | -5.81 | 1.43 | 1.12 | 0.67 | |||
| Total Shareholders' Equity | 83.81M | 169.80M | 197.00M | 151.00M | 91.80M | |||
| TOTAL LIABILITIES AND EQUITY | 1.73B | 1.84B | 1.10B | 579.90M | 565.90M | |||
| Statistics | ||||||||
| Debt/Equity | 17.89 | 8.79 | 4.00 | N/A | 4.17 | |||
| Current Ratio | 6.64 | 5.65 | 7.91 | 1.32 | 6.35 | |||
| Return On Assets (ROA) | 16.25% | 10.97% | 36.46% | 22.26% | -12.76% | |||
| Return On Equity (ROE) | 336.00% | 119.02% | 204.42% | 85.50% | -78.65% | |||
| Return On Invested Capital (ROIC) | 17.00% | 13.71% | 22.64% | 73.76% | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | 21.45% | 17.40% | 90.72% | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 69.74% | 59.78% | 90.72% | N/A | N/A | |||
All data in USD